Sign In
Buy NTLA
$13.02
-0.110 (-0.84%)
At Close: Jun 03, 2026
Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble
11:01am, Friday, 07'th Nov 2025
Despite a narrower Q3 loss, NTLA stock plunges after pulling nex-z milestone guidance amid FDA scrutiny in amyloidosis patients.
2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street
08:45am, Friday, 07'th Nov 2025
Iovance Biotherapeutics and Intellia Therapeutics are two innovative small-cap biotechs. Both companies face serious issues despite Wall Street's high price targets for them.
Intellia Therapeutics, Inc. (NTLA) Q3 2025 Earnings Call Transcript
05:46am, Friday, 07'th Nov 2025
Intellia Therapeutics, Inc. ( NTLA ) Q3 2025 Earnings Call November 6, 2025 6:00 PM EST Company Participants Jason Fredette John Leonard - President, CEO & Director Edward Dulac - Executive Vice Presi
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Misses Revenue Estimates
06:21pm, Thursday, 06'th Nov 2025
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to a loss of $1.34 per share a year ago.
AlphaQuest LLC Sells 29,619 Shares of Intellia Therapeutics, Inc. $NTLA
03:59am, Monday, 03'rd Nov 2025
AlphaQuest LLC reduced its position in Intellia Therapeutics, Inc. (NASDAQ: NTLA) by 57.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Ex
Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130%
09:25am, Sunday, 02'nd Nov 2025
Intellia Therapeutics is featured in Cathie Wood's portfolio and has a high Wall Street price target. The company's leading candidates look somewhat promising, but one of them just hit a major setback
D.A. Davidson & CO. Grows Stock Holdings in Intellia Therapeutics, Inc. $NTLA
06:16am, Thursday, 30'th Oct 2025
D.A. Davidson and CO. increased its stake in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) by 108.0% in the undefined quarter, according to its most recent disclosure with the Securities and Ex
Intellia Therapeutics, Inc. $NTLA Stake Lifted by Cwm LLC
06:16am, Thursday, 30'th Oct 2025
Cwm LLC boosted its stake in Intellia Therapeutics, Inc. (NASDAQ: NTLA) by 22.9% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission
US FDA places clinical hold on Intellia's two gene-editing treatment trials
05:11pm, Wednesday, 29'th Oct 2025
Intellia Therapeutics said on Wednesday that the U.S. Food and Drug Administration has placed a clinical hold on its two late-stage trials testing an experimental gene-editing therapy for a rare disea
Intellia Therapeutics, Inc. (NTLA) Discusses Safety Event and Protocol Pause in MAGNITUDE Clinical Trials of Nex-Z Transcript
11:17am, Monday, 27'th Oct 2025
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Discusses Safety Event and Protocol Pause in MAGNITUDE Clinical Trials of Nex-Z October 27, 2025 8:30 AM EDT Company Participants Jason Fredette John Leonard
Intellia pauses late-stage trials of gene-editing treatment after serious liver event
07:38am, Monday, 27'th Oct 2025
Intellia Therapeutics said on Monday it has temporarily stopped dosing and screening patients in two late-stage studies of its one-time gene-editing treatment for a heart condition after a patient exp
Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)
07:30am, Monday, 27'th Oct 2025
CAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera
Crispr And Intellia: Advancing In Vivo Gene Editing As 2025 Results Strengthen Investment Outlook
08:15am, Friday, 24'th Oct 2025
Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ratin
Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition?
10:25am, Monday, 20'th Oct 2025
Intellia banks on its late-stage gene-editing therapies, lonvo-z and nex-z, that could define its long-term growth phase in the gene editing space.
4 Healthcare Stocks to Buy Now
09:45am, Sunday, 12'th Oct 2025
Healthcare stocks have struggled since interest rates began climbing in 2022. Rising yields pulled capital away from speculative biotech and drug development, pushing valuations lower even as research
